The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general
population and increases further in cancer patients. The risk of VTE is higher in multiple …

Monoclonal gammopathy of undetermined significance is one of the most common pre-
malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are …

Patients with multiple myeloma (MM) have an increased risk of venous thrombosis.
Interestingly, excess risk of venous thromboembolism has been observed among patients …

Patients with multiple myeloma (MM) have an increased risk of deep venous thrombosis
(DVT), particularly when treated with immunomodulatory drugs. Recently, 2 small hospital …

1Avon Haematology Unit, Bristol Haematology and Oncology Centre, Bristol, 2Department
of Haematology, St Helier Hospital, Carshalton, Surrey, UK, 3Department of Haematology …

Summary On February 25, 2009, a panel of international experts on plasma cell dyscrasia
and skeletal disease met to discuss monoclonal gammopathy of undetermined significance …

Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum
monoclonal protein< 30 g/l,< 10% plasma cells in the bone marrow, and absence of end …

Background Lenalidomide is active and well tolerated in relapsed and refractory multiple
myeloma. We conducted a phase I/II trial of the combination of lenalidomide and …

Venous thromboembolism (VTE) is one of the three most common cardiovascular diseases
in the United States. It is also a leading cause of death among patients with cancer. Cancer …

Unexpectedly high rates of venous thromboembolic events (VTE) concurrent with the
introduction of highly effective immune modulating drugs thalidomide and lenolidomide for …